Oil futures ended a four-day string of gains Thursday, with the U.S. benchmark failing to sustain a bounce after data showed a rise in domestic crude-oil inventories.
On the New York Mercantile Exchange, light, sweet crude futures for delivery in February
CLG7, +0.37%
fell 29 cents, or 0.6%, to end at $53.77 a barrel. The contract had traded as high as $54.21 immediately after the Energy Information Administration said crude supplies rose 600,000 barrels last week.
Hot Stocks For 2018: Cross Country Healthcare, Inc.(CCRN)
Advisors’ Opinion:
- [By Lisa Levin]
Losers
Heat Biologics, Inc. (NASDAQ: HTBX) shares tumbled 48.59 percent to close at $1.275 on Thursday after the company priced its $18,000,000 public offering.
InVivo Therapeutics Holdings Corp. (NASDAQ: NVIV) fell 38.77 percent to close at $8.26 on Thursday.
Check-Cap Ltd. (NASDAQ: CHEK) shares tumbled 27.43 percent to close at $8.81.
Achaogen, Inc. (NASDAQ: AKAO) dropped 24.76 percent to close at $11.06 in reaction to a disappointing update from an FDA AdCom panel. The FDA panel voted favorably for the company's Plazcomicin for treatment of adults with complicated urinary tract infections, but also voted against the therapy to be used as a treatment for bloodstream infections.
Anika Therapeutics, Inc. (NASDAQ: ANIK) shares declined 24.68 percent to close at $34.80 after the company posted downbeat quarterly results.
LSC Communications, Inc. (NASDAQ: LKSD) shares fell 24.22 percent to close at $12.64 following wider-than-expected Q1 loss.
Cardinal Health, Inc. (NYSE: CAH) fell 21.42 percent to close at $50.80 following downbeat quarterly profit.
Horizon Global Corporation (NYSE: HZN) dropped 20.42 percent to close at $6.00 following downbeat quarterly earnings.
Hornbeck Offshore Services, Inc. (NYSE: HOS) slipped 20.11 percent to close at $2.90 following wider-than-expected Q1 loss.
Esperion Therapeutics, Inc. (NASDAQ: ESPR) fell 19.28 percent to close at $36.93. Esperion Therapeutics stock lost roughly a third of its value Wednesday after the company reported mixed Phase III results for its leading drug candidate, bempedoic acid. JP Morgan downgraded Esperion Therapeutics from Neutral to Underweight.
Laredo Petroleum, Inc. (NYSE: LPI) declined 17.77 percent to close at $8.98 after the company reported weaker-than-expected Q1 earnings.
The Habit Restaurants, Inc. (NASDAQ: HABT) dipped 16.1 percent to close at $8.60 after the company reported downbeat quarterly results.
Arcadia Biosciences, Inc. (N - [By ]
Activist investor Glenn Welling of Engaged Capital LLC, the insurgent investor agitating for changes at TiVo, Rent-a-Center, on Tuesday, May 15, revealed new positions in Aratana Therapeutics Inc. (PETX) , Cross Country Healthcare Inc. (CCRN) and Finisar Corp. (FNSR)
Hot Stocks For 2018: iShares Nasdaq Biotechnology Index Fund(IBB)
Advisors’ Opinion:
- [By ]
The SPDR S&P Biotech ETF (NYSE:XBI) a good measure of small-cap biotech stocks gained almost 6% yesterday. Meanwhile, the large-cap iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) jumped almost 4%. The biotech buying frenzy helped lift the Nasdaq Composite to a gain of almost 1% in Mondays session.
- [By Benzinga News Desk]
After eking out a modest gain in the week ended April 27, the iShares NASDAQ Biotechnology Index (ETF) (NASDAQ: IBB) pulled back this week amid some not-so-encouraging earnings reports and negative regulatory decisions: Link
- [By Jim Crumly]
Biotech stocks had a big day, with theiShares NASDAQ Biotechnology ETF (NASDAQ:IBB) jumping 2.8%. The broad technology sector slipped, and theTechnology Select Sector SPDR ETF (NYSEMKT:XLK)lost 0.1%.
- [By ]
October was not kind to the biggest names in biotech. While smaller, more speculative biotech names consolidated, the big kids fell off a cliff. The biotech slide accelerated midway through the month, with both the large-cap iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) and the smaller SPDR S&P Biotech ETF slipping more than 5%.
- [By Brian Feroldi, Keith Speights, and Sean Williams]
The iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)– which is an exchange-traded fund that holds nearly 200 biotech stocks — has drastically underperformed the S&P 500 over the last three years. That fact suggests that there are bargains to be found in the biotech space.
Hot Stocks For 2018: Glaukos Corporation(GKOS)
Advisors’ Opinion:
- [By Max Byerly]
Glaukos Corp (NYSE:GKOS) – Equities research analysts at Piper Jaffray lowered their Q3 2019 EPS estimates for Glaukos in a report released on Wednesday, May 9th. Piper Jaffray analyst M. O’brien now anticipates that the medical instruments supplier will earn $0.02 per share for the quarter, down from their previous forecast of $0.03. Piper Jaffray also issued estimates for Glaukos’ Q4 2019 earnings at $0.02 EPS.
- [By Shane Hupp]
Glaukos Corp (NYSE:GKOS) – Equities research analysts at Piper Jaffray lowered their Q3 2019 EPS estimates for Glaukos in a report released on Wednesday, May 9th. Piper Jaffray analyst M. O’brien now anticipates that the medical instruments supplier will earn $0.02 per share for the quarter, down from their previous forecast of $0.03. Piper Jaffray also issued estimates for Glaukos’ Q4 2019 earnings at $0.02 EPS.
- [By Ethan Ryder]
Glaukos Corp (NYSE:GKOS) – Equities research analysts at Piper Jaffray lowered their Q3 2019 EPS estimates for Glaukos in a report released on Wednesday, May 9th. Piper Jaffray analyst M. O’brien now anticipates that the medical instruments supplier will earn $0.02 per share for the quarter, down from their previous forecast of $0.03. Piper Jaffray also issued estimates for Glaukos’ Q4 2019 earnings at $0.02 EPS.
